FVIII: The pro-hemostatic aptamer BT200 is now in Phase 2 for hereditary bleeding disorders. NCT#04677803
VWF: A family of aptamers that inhibit VWF-dependent platelet thrombogenesis (including long-acting BT600 and short-acting BT100) and their complementary reversal agent (BT101) that has in vivo proof of principle and is ready for IND-enabling Manufacturing and Toxicology.
An aptamer ligand for tumor antigen conjugated to toxin (DM1) has in vivo proof of principle in murine xenograft models of liver and lung cancer and is ready for IND-enabling Manufacturing and Toxicology.
Aptamers with high affinity and specificity for certain innate immune cell surface receptors for use in myeloid leukemia, breast cancer, etc.
Aptamers with high affinity and specificity for certain vascular growth factors for use in hematologic or solid malignancies.
IL23: Aptamer with high affinity and specificity for IL23 is currently being evaluated for use in IBD as an orally administered, topical enteric-selective immunomodulator.
SELEX is currently being run against various targets related to IBD, where we plan to exploit the unique option aptamers represent for oral administration of specific, topical immunomodulators to the GI tract.